254 related articles for article (PubMed ID: 30617602)
1. Drug-Lipid-Surfactant Miscibility for the Development of Solid Lipid Nanoparticles.
Trivino A; Gumireddy A; Chauhan H
AAPS PharmSciTech; 2019 Jan; 20(2):46. PubMed ID: 30617602
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization.
Varia JK; Dodiya SS; Sawant KK
Curr Drug Deliv; 2008 Jan; 5(1):64-9. PubMed ID: 18220553
[TBL] [Abstract][Full Text] [Related]
3. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
4. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Thirupathi G; Swetha E; Narendar D
Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
[TBL] [Abstract][Full Text] [Related]
5. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
6. Preparation, Characterization, and In vitro Evaluation of Curcumin- and Resveratrol-Loaded Solid Lipid Nanoparticles.
Gumireddy A; Christman R; Kumari D; Tiwari A; North EJ; Chauhan H
AAPS PharmSciTech; 2019 Mar; 20(4):145. PubMed ID: 30887133
[TBL] [Abstract][Full Text] [Related]
7. Solid lipid nanoparticles for the controlled delivery of poorly water soluble non-steroidal anti-inflammatory drugs.
Kumar R; Singh A; Garg N; Siril PF
Ultrason Sonochem; 2018 Jan; 40(Pt A):686-696. PubMed ID: 28946474
[TBL] [Abstract][Full Text] [Related]
8. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of miscibility and polymorphism of synthetic and natural lipids for nanostructured lipid carrier (NLC) formulations by Raman mapping and multivariate curve resolution (MCR).
Mitsutake H; Ribeiro LNM; Rodrigues da Silva GH; Castro SR; de Paula E; Poppi RJ; Breitkreitz MC
Eur J Pharm Sci; 2019 Jul; 135():51-59. PubMed ID: 31071439
[TBL] [Abstract][Full Text] [Related]
10. Studies on paclitaxel-loaded glyceryl monostearate nanoparticles.
Shenoy VS; Rajyaguru TH; Gude RP; Murthy RS
J Microencapsul; 2009 Sep; 26(6):471-8. PubMed ID: 19169921
[TBL] [Abstract][Full Text] [Related]
11. Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology.
Sarangi B; Jana U; Sahoo J; Mohanta GP; Manna PK
Biomed Microdevices; 2018 Jun; 20(3):53. PubMed ID: 29946758
[TBL] [Abstract][Full Text] [Related]
12. Supercritical fluid precipitation of ketoprofen in novel structured lipid carriers for enhanced mucosal delivery--a comparison with solid lipid particles.
Gonçalves VSS; Matias AA; Rodríguez-Rojo S; Nogueira ID; Duarte CMM
Int J Pharm; 2015 Nov; 495(1):302-311. PubMed ID: 26277371
[TBL] [Abstract][Full Text] [Related]
13. Physical-Chemical Characterization and Formulation Considerations for Solid Lipid Nanoparticles.
Chauhan H; Mohapatra S; Munt DJ; Chandratre S; Dash A
AAPS PharmSciTech; 2016 Jun; 17(3):640-51. PubMed ID: 26292931
[TBL] [Abstract][Full Text] [Related]
14. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
15. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
16. Development of terbinafine solid lipid nanoparticles as a topical delivery system.
Chen YC; Liu DZ; Liu JJ; Chang TW; Ho HO; Sheu MT
Int J Nanomedicine; 2012; 7():4409-18. PubMed ID: 22923986
[TBL] [Abstract][Full Text] [Related]
17. Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique.
Patel MN; Lakkadwala S; Majrad MS; Injeti ER; Gollmer SM; Shah ZA; Boddu SH; Nesamony J
AAPS PharmSciTech; 2014 Dec; 15(6):1498-508. PubMed ID: 25035070
[TBL] [Abstract][Full Text] [Related]
18. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive and comparative studies on nanocytotoxicity of glyceryl monooleate- and phytantriol-based lipid liquid crystalline nanoparticles.
Jagielski J; Przysiecka Ł; Flak D; Diak M; Pietralik-Molińska Z; Kozak M; Jurga S; Nowaczyk G
J Nanobiotechnology; 2021 Jun; 19(1):168. PubMed ID: 34082768
[TBL] [Abstract][Full Text] [Related]
20. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
